(DLCL04) With Rituximab Dose-Dense

Lymphoma (DLBCL) Treated In The Phase III Randomized
Trial (DLCL04) With Rituximab Dose-Dense Chemotherapy
Followed By Intensified High-Dose Chemotherapy and
Autologous Stem Cell Transplantation (HDC+ASCT) Or
Standard Rituximab Dose Dense Chemotherapy: A Study
of The Fondazione Italiana Linfomi (FIL)
by Umberto Vitolo, Annalisa Chiappella, Ercole Brusamolino, Emanuele Angelucci,
Giuseppe Rossi, Angelo Michele Carella, Andrea Evangelista, Caterina Stelitano,
Monica Balzarotti, Francesco Merli, Gianluca Gaidano, Manuel Gotti, Vincenzo
Pavone, Luigi Rigacci, Francesco Zaja, Chiara Rusconi, Amalia De Renzo, Graziella
Pinotti, Michele Pizzuti, Michele Spina, Maria Cantonetti, Giorgina Specchia, Patrizia
Pregno, Eleonora Russo, Alessandra Tucci, Maria Giuseppina Cabras, Stefano A
Pileri, Alessandro Levis, and Maurizio Martelli
Blood
Volume 122(21):4340-4340
November 15, 2013
©2013 by American Society of Hematology
PFS by BM involvement.
Annalisa Chiappella et al. Blood 2013;122:4340
©2013 by American Society of Hematology